Interleukin-2 receptor (IL-2R), Interleukin-1 receptor (IL-1R), Interferon-gamma receptor (IFNGR), and Tumor necrosis factor receptor (TNFR)

This entry represents a group of key cytokine receptors—Interleukin-2 receptor (IL-2R), Interleukin-1 receptor (IL-1R), Interferon-gamma receptor (IFNGR), and Tumor Necrosis Factor receptor (TNFR)—that are central to the regulation of the immune system. These receptors are expressed on various immune cells, including T cells, B cells, and macrophages, where they mediate signals for cell proliferation, differentiation, and the inflammatory response (Liao et al., 2013, Immunity; Dinarello, 2011, Blood). Dysregulation of these signaling pathways is a hallmark of numerous pathologies, including rheumatoid arthritis, inflammatory bowel disease, and cytokine release syndrome (Brenner et al., 2015, Nature Reviews Immunology). Consequently, these receptors and their ligands are primary targets for biological therapies, such as monoclonal antibodies and decoy receptors, aimed at modulating immune activity. For example, Basiliximab and Anakinra directly target the IL-2 and IL-1 receptors, respectively, while Etanercept acts as a decoy receptor for TNF-alpha. While highly effective in treating chronic inflammation and certain cancers, targeting these receptors carries risks of systemic immunosuppression and opportunistic infections (Shtrichman & Samuel, 2001, Current Opinion in Microbiology). Therapeutic monitoring often involves measuring serum cytokine levels or downstream inflammatory markers like C-reactive protein.

Other names

Interleukin-2 receptorInterleukin-1 receptorInterferon-gamma receptorTumor necrosis factor receptorCD25CD121aCD119CD120aCD120bCytokine receptors

Mechanisms include competitive antagonism of the receptor, neutralization of the cytokine ligand to prevent receptor activation, and receptor agonism to stimulate specific immune subsets.